Xenetic Biosciences, Inc. (XBIO) stock
XBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/3064% below fair value
$1.61+0.12 (+8.05%)
Close on Nov 17, 2026Market cap $3.77MP/E –Yield –
Xenetic Biosciences r&d expenses
Research and development expenses are spending on new products and technology.
Xenetic Biosciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $2.74M, down 6.9% year over year. For fiscal 2025 it was $3.07M, down 6.8% from the year before. Over ten years it grew -1.1% a year on average. The highest annual figure on record is $43.74M in fiscal 2016.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.07M | -6.8% |
| FY2024 | Dec 31, 2024 | $3.29M | -5.9% |
| FY2023 | Dec 31, 2023 | $3.49M | -26.7% |
| FY2022 | Dec 31, 2022 | $4.77M | +50.8% |
| FY2021 | Dec 31, 2021 | $3.16M | +82.7% |
| FY2020 | Dec 31, 2020 | $1.73M | -64.6% |
| FY2019 | Dec 31, 2019 | $4.89M | +69.5% |
| FY2018 | Dec 31, 2018 | $2.88M | -29.0% |
| FY2017 | Dec 31, 2017 | $4.06M | -90.7% |
| FY2016 | Dec 31, 2016 | $43.74M | +1173.7% |
| FY2015 | Dec 31, 2015 | $3.43M | -45.7% |
| FY2014 | Dec 31, 2014 | $6.32M | +106.6% |
| FY2013 | Dec 31, 2013 | $3.06M | +57.5% |
| FY2012 | Dec 31, 2012 | $1.94M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $552.01K | -15.9% |
| Q1 FY2026 | Mar 31, 2026 | $661.44K | -24.8% |
| Q4 FY2025 | Dec 31, 2025 | $773.42K | -25.8% |
| Q3 FY2025 | Sep 30, 2025 | $756.48K | +105.6% |
| Q2 FY2025 | Jun 30, 2025 | $656.56K | -29.7% |
| Q1 FY2025 | Mar 31, 2025 | $879.03K | -6.9% |
| Q4 FY2024 | Dec 31, 2024 | $1.04M | +6.8% |
| Q3 FY2024 | Sep 30, 2024 | $367.99K | -63.9% |
| Q2 FY2024 | Jun 30, 2024 | $933.77K | +3.4% |
| Q1 FY2024 | Mar 31, 2024 | $944.32K | +58.6% |
| Q4 FY2023 | Dec 31, 2023 | $975.63K | -53.0% |
| Q3 FY2023 | Sep 30, 2023 | $1.02M | -7.3% |
| Q2 FY2023 | Jun 30, 2023 | $903.24K | -26.5% |
| Q1 FY2023 | Mar 31, 2023 | $595.28K | -23.7% |
| Q2 FY2022 | Jun 30, 2022 | $2.08M | +296.1% |
| Q1 FY2022 | Mar 31, 2022 | $1.10M | +74.9% |
| Q4 FY2021 | Dec 31, 2021 | $1.23M | +150.4% |
| Q3 FY2021 | Sep 30, 2021 | $780.15K | +36.1% |
| Q2 FY2021 | Jun 30, 2021 | $524.55K | +70.4% |
| Q1 FY2021 | Mar 31, 2021 | $629.73K | +75.1% |
| Q4 FY2020 | Dec 31, 2020 | $490.79K | +17.6% |
| Q3 FY2020 | Sep 30, 2020 | $573.06K | -83.7% |
| Q2 FY2020 | Jun 30, 2020 | $307.90K | -36.8% |
| Q1 FY2020 | Mar 31, 2020 | $359.65K | -22.5% |
| Q4 FY2019 | Dec 31, 2019 | $417.40K | -18.9% |
| Q3 FY2019 | Sep 30, 2019 | $3.52M | +378.4% |
| Q2 FY2019 | Jun 30, 2019 | $487.52K | -47.4% |
| Q1 FY2019 | Mar 31, 2019 | $463.78K | -34.3% |
| Q4 FY2018 | Dec 31, 2018 | $514.73K | -52.3% |
| Q3 FY2018 | Sep 30, 2018 | $735.88K | -16.8% |
| Q2 FY2018 | Jun 30, 2018 | $927.07K | +6.1% |
| Q1 FY2018 | Mar 31, 2018 | $706.27K | -42.2% |
| Q4 FY2017 | Dec 31, 2017 | $1.08M | -97.3% |
| Q3 FY2017 | Sep 30, 2017 | $884.80K | -0.8% |
| Q2 FY2017 | Jun 30, 2017 | $873.84K | -60.4% |
| Q1 FY2017 | Mar 31, 2017 | $1.22M | – |
| Q4 FY2016 | Dec 31, 2016 | $40.21M | – |
| Q3 FY2016 | Sep 30, 2016 | $891.83K | – |
| Q2 FY2016 | Jun 30, 2016 | $2.21M | – |
See a number that looks wrong?